15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Coherus BioSciences Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $4.00 to $12.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.67 sits 499% above the current $1.45. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-1.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Coherus BioSciences Inc.
As of Jul, 3 of 3 firms rate CHRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CHRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.29 – $-0.16 · 2 analysts · -32% YoY
Next period, 2 analysts expect Coherus BioSciences Inc to earn $-0.23 a share (range $-0.29 – $-0.16), versus $-0.33 a year earlier. Full-year consensus is $-0.74, growing to $-1.02 the year after.
REVENUE · NEXT QUARTER
$16.1M
Range $14.9M – $17.4M · 2 analysts · +39% YoY
Revenue is expected to reach $16.1M (range $14.9M – $17.4M), +38.8% year-over-year. Full-year consensus is $73.0M, rising to $100.1M next year.
Top analysts covering Coherus BioSciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CHRS.
#1
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$7.00+383.6% to target
Overall win rate
35%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #302
Buy
$10.00+590.8% to target
Overall win rate
32%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #360
Buy
$4.00+176.3% to target
Overall win rate
30%
+ Follow
#4
Ashwani Verma
UBS
Hold
$1.10-24.0% to target
Coverage
—
+ Follow
#5
MN
Michael Nedelcovych
TD Cowen
Buy
No targeton CHRS
Coverage
—
+ Follow
CHRS stock forecast FAQ
What is CHRS's average 12-month price target?+
The 2 analysts with a live target average $8.67 for Coherus BioSciences Inc over the next 12 months, ranging from a $12.00 high to a $4.00 low.
Is CHRS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CHRS?+
The Street-high target is $12.00, and the Street-low is $4.00 (Maxim Group). The average of all 2 active targets is $8.67.
How many Wall Street analysts cover CHRS?+
3 analysts have an active rating on Coherus BioSciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CHRS?+
Among analysts who currently cover CHRS, Douglas Tsao of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #212). Their current call is Buy with a $7.00 target.
What is Coherus BioSciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.29 – $-0.16) across 2 analysts. Full-year EPS is projected at $-0.74, rising to $-1.02 the following year.
How much revenue is Coherus BioSciences Inc expected to report next quarter?+
Consensus revenue is $16.1M (range $14.9M – $17.4M). Full-year revenue is projected at $73.0M, growing to $100.1M next year.
Have analysts been upgrading or downgrading CHRS lately?+
As of Jul, 3 of 3 firms rate CHRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CHRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
